Dysmenorrhea Treatment Market by Type, Treatment, Distribution Channel, End-Users

List of Tables

[189 Pages Report] The Dysmenorrhea Treatment Market size was estimated at USD 7.16 billion in 2023 and expected to reach USD 7.80 billion in 2024, at a CAGR 8.98% to reach USD 13.09 billion by 2030.

Dysmenorrhea treatment refers to the therapeutic approaches for managing and alleviating the pain and discomfort associated with dysmenorrhea or menstrual cramps. Dysmenorrhea is a prevalent condition affecting a significant proportion of menstruating individuals, characterized by painful abdominal cramping that occurs during or before their menstrual periods. The treatments for treating dysmenorrhea aim to reduce the pain, improve quality of life, and minimize disruption to daily activities. Meanwhile, the rising awareness about women's reproductive health and government initiatives & programs supporting healthcare facilities for women contribute significantly to the expansion of dysmenorrhea-related treatments. The increasing number of clinical trials and huge investments by healthcare entities have also contributed to the large-scale dysmenorrhea treatments & diagnosis. However, the lack of reimbursement policies and strict regulations associated with the drugs for menstrual pains is a significant challenge for dysmenorrhea treatment providers. Companies are continuously working toward cutting treatment costs and investing in research activities for novel medications to remain competitive in this evolving market landscape. Moreover, the recent advancements in the therapy of dysmenorrhea and increasing adoption of wearable technology along with digital health services are frequently contributing to the future expansion of dysmenorrhea treatment. Additionally, harnessing data-driven insights using artificial intelligence and machine learning can also aid in developing personalized treatment plans and identifying patterns leading to new therapeutic interventions in dysmenorrhea treatments.

KEY MARKET STATISTICS
Base Year [2023]	USD 7.16 billion
Estimated Year [2024]	USD 7.80 billion
Forecast Year [2030]	USD 13.09 billion
CAGR (%)	8.98%

Type: Wide occurrence of primary dysmenorrhea and extensive need for pain relief management

Primary dysmenorrhea is experienced by up to 90% of women which is caused by uterine contractions and prostaglandin release during menstruation. The need for primary dysmenorrhea treatment mainly revolves around pain relief and management. Additional treatments include oral contraceptives that help regulate hormone levels, heat application to ease muscle tension, and lifestyle modifications such as exercise and stress reduction. Secondary dysmenorrhea is menstrual pain caused by an underlying medical condition, including endometriosis, pelvic inflammatory disease, or uterine fibroids. The need for secondary dysmenorrhea treatment focuses on addressing the root cause of the pain while also providing symptom relief. The treatment options for secondary dysmenorrhea vary depending on the specific medical condition. Endometriosis treatments may include hormonal therapy, surgical interventions such as laparoscopic surgery, and anti-inflammatory medications. The cases having pelvic inflammatory disease is the underlying cause of secondary dysmenorrhea, antibiotics are often prescribed to treat the infection.

Treatment: Adoption of hysterectomy treatment to provide permanent relief from dysmenorrhea

Medications are often the first line of treatment for dysmenorrhea. Nonsteroidal anti-inflammatory drugs (NSAIDs), including ibuprofen and naproxen, effectively reduce pain and inflammation associated with menstrual cramps. These medications are purchased over the counter or prescribed by a healthcare professional. Surgical intervention treatment is reserved for patients with severe dysmenorrhea caused by underlying conditions such as endometriosis or uterine fibroids. Laparoscopic surgery is minimally invasive and can effectively remove adhesions or fibroids causing the pain. In extreme cases, a hysterectomy, which is the removal of the uterus, may be performed to provide permanent relief from dysmenorrhea. Moreover, psychological interventions can be beneficial in addressing the emotional distress linked to dysmenorrhea and enhancing overall coping abilities. Most used psychological therapies include cognitive behavioral therapy (CBT), relaxation techniques (deep breathing, progressive muscle relaxation), and biofeedback (monitoring physiological processes such as heart rate variability, muscle tension, or skin temperature). Furthermore, various non-pharmacological approaches have gained popularity due to their potential benefits in managing dysmenorrhea symptoms without causing significant side effects. Few alternative treatments, including acupuncture, transcutaneous electrical nerve stimulation (TENS), aromatherapy, yoga, and dietary supplements, offer a variety of options for individuals seeking non-pharmacological methods to manage dysmenorrhea symptoms and provide comprehensive care options for patients experiencing menstrual pain.

Distribution Channel: Growing preference for online pharmacies due to their convenience, discreteness, and competitive pricing of medications and pain relief patches

In treating dysmenorrhea, hospital pharmacies are crucial in providing patients with immediate and appropriate medication. Hospital pharmacies often have a wide range of over-the-counter (OTC) and prescription medications to treat various types of dysmenorrhea, including nonsteroidal anti-inflammatory drugs (NSAIDs), analgesics, antispasmodics, and hormonal treatments, including oral contraceptives. Online pharmacies are increasingly popular for purchasing dysmenorrhea treatments due to their convenience, discreteness, and competitive pricing. Online platforms offer a variety of products, including traditional OTC medications and alternative remedies such as herbal supplements and heat patches. The preference for online pharmacies is higher among those seeking privacy or living in remote areas with limited access to physical retail outlets. Retail pharmacies remain an essential distribution channel for dysmenorrhea treatments as they offer easy access to medication without needing a prior appointment with a healthcare professional. These pharmacies stock various OTC medications, including ibuprofen, naproxen, and aspirin. Retail pharmacies cater to consumers preferring face-to-face interaction with pharmacists for personalized advice and recommendations.

End-Users: Increasing adoption of dysmenorrhea treatment in the homecare segment as it is easily accessible and cost-effective

In the homecare sector, end-users prefer easily accessible and cost-effective treatment options to manage dysmenorrhea symptoms. These include over-the-counter (OTC) medications, such as nonsteroidal anti-inflammatory drugs (NSAIDs), ibuprofen, and naproxen, and natural remedies, including heat therapy and herbal supplements. Homecare also involves alternative therapies such as yoga, acupuncture, and massage that have shown promising results in alleviating menstrual pain. End-users prefer hospitals in need of more intensive care or advanced interventions for treating severe cases of dysmenorrhea. Surgical treatments may also be recommended in patients with underlying gynecological conditions contributing to severe dysmenorrhea symptoms. Endometriosis-related menstrual pain can be treated in laparoscopic surgery by specialized gynecological surgeons in hospitals. Specialty clinics cater to end-users seeking specialized care from healthcare professionals with expertise in women's health issues, such as gynecologists, reproductive endocrinologists, and pelvic pain specialists. These clinics offer personalized treatment plans, including prescription medications, hormonal therapy, physical therapy, or psychological counseling.

Regional Insights

In American countries, including the United States and Canada, a large percentage of the female population experiences menstrual cramps, including dysmenorrhea. These countries witness various efforts to research and develop effective treatments for this condition with greater awareness of women's health issues. European Union countries have advanced healthcare systems that prioritize women's health, leading to significant funding for research on dysmenorrhea treatment options. For instance, the European Medicines Agency (EMA) has approved various medications targeting menstrual pain relief across European countries. Furthermore, China, Japan, and India are key markets within the Asia-Pacific region for dysmenorrhea treatment due to their large populations of women experiencing menstrual pain. Traditional medicine plays a crucial role in addressing dysmenorrhea in these countries. Moreover, research initiatives in this region explore the efficacy of alternative therapies, such as acupuncture and moxibustion, in treating dysmenorrhea. In Japan, a mix of traditional and modern medical approaches is adopted to address women's health issues, with patented medications such as Loxoprofen being prescribed for menstrual pain relief. India has observed an increase in investment in menstrual hygiene management and access to affordable healthcare with its growing awareness about women's health issues. The need for effective dysmenorrhea treatments worldwide varies across regions based on cultural factors, healthcare infrastructure, and awareness about women's health issues. Innovations in research and development provide promising opportunities for advancements in dysmenorrhea treatment options.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Dysmenorrhea Treatment Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Dysmenorrhea Treatment Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Dysmenorrhea Treatment Market, highlighting leading vendors and their innovative profiles. These include AA Pharma Inc., Abbott Laboratories, AbbVie Inc., Alfa Pharma GmbH, Alvogen, Inc., ASKA Pharmaceutical Co., Ltd., Bayer AG, Comforte Cream by PMS4PMS, LLC, Cora Life by LYV Life, Inc., Cumberland Pharmaceuticals Inc., Dr. Reddy's Laboratories Ltd., Endo Pharmaceuticals Inc., F. Hoffmann-La Roche AG, Ferring B.V., Gedeon Richter Plc., GlaxoSmithKline PLC, Haleon PLC, Hikma Pharmaceuticals PLC, Johnson & Johnson Services, Inc., LGM Pharma, Livia by iPulse Medical Ltd., Lupin Pharmaceuticals, Inc., Merck & Co., Inc., Micro Labs Limited, Myoovi, Myovant Sciences by Sumitovant Biopharma, Inc., Novartis AG, Ovira, Perrigo Company PLC, Pfizer Inc., Rael, Inc., Sanofi S.A., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited., Teva Pharmaceutical Industries Ltd., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Dysmenorrhea Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

Type
- Primary Dysmenorrhea
- Secondary Dysmenorrhea

Treatment
- Medication
  - Combined Oral Contraceptive Pills
  - Cox-2 Inhibitors
  - Non-Steroidal Anti-Inflammatory Drugs
  - Over-The-Counter Medications
  - Transdermal Glyceryl Trinitrate

Surgery
- Hysterectomy
- Intrauterine Device
- Laparoscopic Uterosacral Nerve Ablation
- Levonorgestrel Intrauterine System (LN-IUS)
- Presacral Neurectomy

Therapeutics
- Alternative Therapies
- Psychological Therapies

Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy

End-Users
- Homecare
- Hospitals
- Specialty Clinics

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Dysmenorrhea Treatment Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Dysmenorrhea Treatment Market?

3. What are the technology trends and regulatory frameworks in the Dysmenorrhea Treatment Market?

4. What is the market share of the leading vendors in the Dysmenorrhea Treatment Market?

5. Which modes and strategic moves are suitable for entering the Dysmenorrhea Treatment Market?

Product Code: MRR-742BD517DA92

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Prevalence of dysmenorrhea and the need for effective treatment options
  - 5.1.1.2. Growing awareness about women's reproductive health and government initiatives to expand healthcare for women
- 5.1.2. Restraints
  - 5.1.2.1. Issues associated with product recalls for dysmenorrhea drugs and devices
- 5.1.3. Opportunities
  - 5.1.3.1. Advancements in therapy for dysmenorrhea and the emergence of novel drugs
  - 5.1.3.2. Adoption of wearable technology and the proliferation of digital health
- 5.1.4. Challenges
  - 5.1.4.1. Societal barriers and stigmatization regarding dysmenorrhea management
5.2. Market Segmentation Analysis
- 5.2.1. Type: Wide occurrence of primary dysmenorrhea and extensive need for pain relief management
- 5.2.2. Treatment: Adoption of hysterectomy treatment to provide permanent relief from dysmenorrhea
- 5.2.3. Distribution Channel: Growing preference for online pharmacies due to their convenience, discreteness, and competitive pricing of medications and pain relief patches
- 5.2.4. End-Users: Increasing adoption of dysmenorrhea treatment in the homecare segment as it is easily accessible and cost-effective
5.3. Market Trend Analysis
- 5.3.1. Strong dysmenorrhea treatment landscape in the Americas characterized by advanced pharmaceutical options and growing innovation by startups, aiming to provide personalized, digital and patient-centered solutions
- 5.3.2. Rising women's health awareness necessitates extensive clinical trials and dysmenorrhea treatment commercialization across APAC
- 5.3.3. Regulatory compliance emphasizes the funding, R&D, clinical trials, and approvals for dysmenorrhea treatment in the EMEA region
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework Analysis

6. Dysmenorrhea Treatment Market, by Type

6.1. Introduction
6.2. Primary Dysmenorrhea
6.3. Secondary Dysmenorrhea

7. Dysmenorrhea Treatment Market, by Treatment

7.1. Introduction
7.2. Medication
7.3. Surgery
7.4. Therapeutics

8. Dysmenorrhea Treatment Market, by Distribution Channel

8.1. Introduction
8.2. Hospital Pharmacy
8.3. Online Pharmacy
8.4. Retail Pharmacy

9. Dysmenorrhea Treatment Market, by End-Users

9.1. Introduction
9.2. Homecare
9.3. Hospitals
9.4. Specialty Clinics

10. Americas Dysmenorrhea Treatment Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Dysmenorrhea Treatment Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Dysmenorrhea Treatment Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
- 13.3.1. Mithra Submits Marketing Approval Application in Japan to Combat Dysmenorrhea
- 13.3.2. Chime Biologics and Hope Medicine Enter Manufacturing Agreement to Speed up the Launch of First-in-class Antibody Drug HMI-115 Targeting Endometriosis and Androgenic Alopecia
- 13.3.3. Mithra to Receive EUR 2.5 Million from Fuji Pharma for Dysmenorrhea Treatment in Japan
- 13.3.4. Sumitomo Pharma and Pfizer in Canada Receive Health Canada Approval for MYFEMBREE
- 13.3.5. Gedeon Richter and Sumitomo Pharma Receive Positive CHMP Opinion for RYEQO for Treatment of Endometriosis
- 13.3.6. How New Tech from Montreal Could Help the Fight Against Period Cramps
- 13.3.7. Chugai and Biofourmis Enter into New Partnership Focused on Data-Driven Virtual Care for Endometriosis-Related Pain
- 13.3.8. Dare Bioscience Begins Phase I Trial of Primary Dysmenorrhea Therapy
- 13.3.9. Healthtech Startup Ovira is Helping Women Tackle a Key Problem - Drug-Free Period Pain Relief
- 13.3.10. Cora Reimagines Period Care with a New Beauty-Inspired Look and Expanded Wellness Portfolio to Make Comfort Accessible for Everyone

14. Competitive Portfolio

14.1. Key Company Profiles
14.2. Key Product Portfolio